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randomised controlled trial
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Abstract
Background: Despite evidence from clinical trials that intravenous (IV) thrombolysis is a cost-effective treatment for
selected acute ischaemic stroke patients, there remain large variations in the rate of IV thrombolysis delivery
between stroke services. This study is evaluating whether an enhanced care pathway delivered by paramedics (the
Paramedic Acute Stroke Treatment Assessment (PASTA)) could increase the number of patients who receive IV
thrombolysis treatment.
Methods:
Study design: Cluster randomised trial with economic analysis and parallel process evaluation.
Setting: National Health Service ambulance services, emergency departments and hyper-acute stroke units within
three geographical regions of England and Wales.
Randomisation: Ambulance stations within each region are the units of randomisation. According to station allocation,
paramedics based at a station deliver the PASTA pathway (intervention) or continue with standard stroke care (control).
Study intervention: The PASTA pathway includes structured pre-hospital information collection, prompted pre-notification,
structured handover of information in hospital and assistance with simple tasks during the initial hospital assessment.
Study-trained intervention group paramedics deliver this pathway to adults within 4 h of suspected stroke onset.
Study control: Standard stroke care according to national and local guidelines for the pre-hospital and hospital
assessment of suspected stroke.
Participants: Participants enrolled in the study are adults with confirmed stroke who were assessed by a study paramedic
within 4 h of symptom onset.
Primary outcome: Proportion of participants receiving IV thrombolysis.
Sample size: 1297 participants provide 90% power to detect a 10% difference in the proportion of patients receiving IV
thrombolysis.
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Discussion: The results from this trial will determine whether an enhanced care pathway delivered by paramedics can
increase thrombolysis delivery rates.
Trial registration: ISRCTN registry, ISRCTN12418919. Registered on 5 November 2015.
Keywords: Stroke, Pre-hospital research, Paramedics, RCT, Economic evaluation, Parallel process evaluation
Background
Stroke is responsible for a high global burden of mortal-
ity and disability [1]. In the UK it remains the third lead-
ing cause of death and the single largest cause of adult
disability with an economic impact of approximately £7
billion per year [2].
The most widely used cost-effective emergency treat-
ment is intravenous (IV) thrombolysis using recombin-
ant tissue plasminogen activator for selected ischaemic
stroke cases within 4.5 h of symptom onset [3]. Despite
evidence from clinical trials, related guidelines and pol-
icy, national audit continues to show large variations in
the rate of IV thrombolysis delivery between services
and diurnal variations within services [4, 5]. Outcomes
are highly time dependent [3, 6]. Within 60–90 min of
symptom onset, only four suitable patients need to be
treated for one person to be free from disability, whereas
at 270 min the same impact would require nine patients
to be treated [3]. In 2014, only 11% of total stroke ad-
missions in the National Health Service (NHS) were
treated with IV thrombolysis against an aspirational tar-
get of 20%, with a median door to treatment time of 54
min despite a target of < 40 min [4]. Benefits for patients
and social care resources would be substantially im-
proved if more eligible patients recieved IV thromboly-
sis, and if they were treated sooner.
Most stroke services have found it challenging to im-
prove IV thrombolysis rates and reduce treatment delays
in hospital (i.e. door to needle time (DTNT)), particu-
larly because of access to brain imaging (i.e. door to scan
time (DTST)). Brain imaging is a vital component of as-
sessment to exclude haemorrhagic stroke and patients
with established ischaemic changes where IV thromboly-
sis would be futile and potentially harmful. International
clinical guidelines state that brain imaging should be
performed immediately when a patient with IV thromb-
olysis potential arrives [7, 8]. An urgent scan is also
indicated for other patients presenting with stroke symp-
toms, including those taking anticoagulation medication
and those for whom a haemorrhage is suspected. Urgent
treatments for these patients can include reversal of
anticoagulation, intravenous medication to lower high
blood pressure and possible neurosurgical intervention
[8]. Although across the NHS brain imaging was
achieved within 1 h for 43% of stroke admissions in
2014, there was wide variation between services, and the
low IV thrombolysis rate suggests that patients with the
most to gain from rapid radiological assessment were
not actively being identified [4]. An improvement in the
early identification of patients who meet the criteria for
an urgent scan could lead to a cost-effective reduction in
dependency, mainly through an increase in the rate and
speed of IV thrombolysis treatment, but also by improv-
ing access to other treatments and organised stroke care.
To date, most service interventions to increase IV
thrombolysis and reduce delays have focussed on re-
sponses after patient admission to the Emergency De-
partment (ED) or Hyper-Acute Stroke Unit (HASU).
Where improvements have been seen, this typically re-
flects highly resourced, large volume urban centres, but
even these may rely upon initial patient assessment by
nursing and junior medical staff at nights and on week-
ends. In some settings, the standard approach is remote
stroke specialist assessment by video link or telephone,
increasing the reliance upon non-specialist staff for rapid
and accurate information collection and communication
at the bedside.
In the pre-hospital setting, there is good evidence that
the paramedic sensitivity for stroke identification using
the Face Arm Speech Test (FAST) is equivalent to that
of non-specialist ED staff [9] and that ambulance contact
to the ED to provide advance notice of admission (pre-
notification) can have a positive impact [10, 11].
However, despite existing operational guidelines within
ambulance services to encourange identification of sus-
pected stroke and symptom onset time, pre-notification
does not occur systematically in clinical practice, and
the significance of other information collected by para-
medics for IV thrombolysis decision making may not be
realised during patient handover at hospital (e.g. current
medication and recent medical history). Although
healthcare policy supports ongoing development of the
paramedic role [12], there has been no rigorous examin-
ation of how paramedics could best contribute to im-
proving DTNT and DTST. A Swedish randomised trial
showed that IV thrombolysis rates and hospital treat-
ment delays significantly improved after paramedics
were provided with training and the emergency status of
stroke ambulance dispatch was raised [13]. An observa-
tional study in Helsinki collecting data before and after a
simple training package for ambulance personnel
showed that on-scene time reduced by an average of 2.5
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min, but there was insufficient power to assess the
impact on IV thrombolysis treatment rates [14]. An
alternative model of ‘mobile stroke units’ (adapted am-
bulances with computerised tomography (CT) scanner
and neurologist on board or video link to a stroke spe-
cialist) has been shown to reduce service-level call to
needle times (CTNTs) by 15 min in dense urban areas,
but the impact on outcomes must be balanced against
the additional costs and technical challenges [15–17]. As
the ambulance transfer time from scene to hospital in
most of England is already short, this model is unlikely
to be adopted [18].
Feedback from the hospital team to paramedics about in-
dividual stroke assessments appears to improve future ad-
herence to pre-hospital protocols including pre-notification
[19], but no process exists to routinely facilitate this. For
unselected emergency admissions, a paramedic-initiated
standardised communication approach appears to improve
the accuracy and efficiency of handover [20], and there may
be value in a format which is stroke specific. In acute med-
ical settings there is increasing evidence that checklists are
effective for improving patient safety and protocol adher-
ence [21], and a paramedic protocol could include simple
questions to prompt important hospital care processes (e.g.
confirm that communication has been established with the
stroke specialist).
This study will evaluate the clinical and cost effective-
ness of a paramedic-initiated ambulance care pathway
which seeks to facilitate the hospital assessment of patients
presenting with acute stroke symptoms in order to specif-
ically increase IV thrombolysis rates and reduce treatment
delays. Patient and professional views about the care path-
way will also be described. This Paramedic Acute Stroke
Treatment Assessment (PASTA) pathway consists of
structured pre-hospital information collection, prompted
pre-notification, structured handover of information in
hospital, assistance with simple tasks during the first 15
min of hospital assessment, a checklist to confirm progress
after 15min and a paramedic request for feedback before
departure. The pathway has been developed through sys-
tematic review of the literature regarding enhanced roles
of paramedics as well as developmental workshops with
clinicians and support personnel in order to define profes-
sional roles and operational boundaries which are feasible
whilst maximizing value for patient care.
Methods
Study aim and objectives
Aim
The aim of the study is to determine the clinical and
cost effectiveness of an enhanced PASTA pathway.
Objectives
The study objectives are as follows:
 To determine whether the PASTA pathway
improves patient care and outcomes. Primary
outcome: proportion of patients receiving IV
thrombolysis. Secondary outcomes: stroke severity
24 h after IV thrombolysis (National Institutes of
Health Stroke Scale (NIHSS) [22]), complications
after IV thrombolysis, inpatient mortality, discharge
destination, discharge dependency (modified Rankin
Scale (mRS) score [23]), assistance at discharge, 90
day dependency (mRS), 90 day destination,
assistance at 90 days
 To describe the impact of the PASTA pathway on
time intervals from emergency call and hospital
admission to first brain imaging, IV thrombolysis
treatment (if given), HASU admission and formal
assessment of swallowing safety
 To describe the number and subsequent diagnoses
of suspected stroke patients who travelled to
hospital with a study paramedic but following
assessment at hospital were not given a diagnosis of
stroke (‘stroke mimics’)
 To determine the cost effectiveness of the PASTA
pathway relative to standard NHS stroke care
 To report patient and professional views and
experiences about the PASTA pathway.
Study design
This study is a cluster randomised controlled trial (RCT)
with embedded economic analysis and process evaluation.
Participants receive either the PASTA pathway (interven-
tion group) or standard stroke care (comparison group).
The study is presented according to the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
guidelines. Figure 1 shows a SPIRIT schedule of enrolment,
interventions and assessments. The SPIRIT 221 checklist is
provided in Additional file 1.
Study setting
The study is taking place within ambulance services and
a selected number of receiving hospital sites. Hospital
sites within each region represent a range of service de-
signs and historical efficiencies in the provision of acute
stroke care. All hospital sites receive emergency stroke
admissions and provide 24-h access to brain imaging
and a stroke specialist opinion in order to make an IV
thrombolysis decision.
Randomisation
PASTA is a cluster RCT in which the unit of randomisation
is an ambulance station. Clusters comprise the paramedics
based within stations. Prior to the start of the trial within
each ambulance service, those ambulance stations which
feed into a study hospital were randomised to delivering
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the PASTA pathway or to continue with standard
stroke care.
Stations within each service were stratified according
to size (categorised as small, medium or large according
to the personnel and resources available) and distance
from the nearest study hospital admitting stroke patients
(distance categorised as near or far, reflecting the local
geography of each ambulance service). The use of these
stratifying variables ensured that PASTA care para-
medics (intervention) and standard care paramedics
(control) were approximately equally matched in terms
of operational characteristics.
Paramedics based at stations randomised to continu-
ing standard care were informed that there is an ongoing
study of pre-hospital assessment for stroke patients but
were not given any further information about the inter-
vention. Paramedics based at stations randomised to de-
liver the PASTA pathway were asked to complete
study-specific training (see also the ‘Staff training and
awareness’ section later in the paper). All paramedics
could opt out of the study if they wished.
Study treatments
PASTA pathway (intervention group)
The PASTA pathway is delivered by study-trained inter-
vention group paramedics. The pathway is delivered to
the following patients: aged 18 years and over; FAST [9]
positive or any presentation of new focal neurological
symptoms which indicate acute stroke in the paramedic’s
routine clinical judgement; within 4 h of last known to
be without new stroke symptoms in the paramedic’s
judgement; admission to a study hospital.
A summary of the PASTA pathway is shown in Fig. 2.
It consists of the following stages:
1. Information. The paramedic will seek additional
information at the scene which is routinely
considered during IV thrombolysis treatment
decisions but is typically not obtained until after
hospital admission. This will include:
 The presence of language (dysphasia) or visual
(visuospatial) problems during a simple clinical
examination, which may indicate a level of
stroke severity more likely to be considered for
IV thrombolysis treatment than FAST symptoms
alone
 Prescription of anticoagulant medication, which
would require additional urgent measurement of
blood clotting indices before a IV thrombolysis
decision could be made. This medication is also
an additional indication for urgent brain imaging
by itself, as a stroke due to haemorrhage would
trigger urgent reversal of its effects
 A recent medical history of surgery or bleeding,
which might exclude IV thrombolysis treatment
because of an increased risk of uncontrollable
haemorrhage
Study period
Allocation Interventions Post-intervention
-t1 t0 t1 t2 t3
Allocation Allocation according to 
attending pre-randomised 
paramedic
x
Interventions PASTA pathway x
Standard acute stroke 
care
x
Enrolment Eligibility screen x
Informed consent x
Data 
collection 
day 1
Demography x
Stroke characteristics x
Primary outcome (iv 
thrombolysis treatment)
x
Other stroke treatments 
received
x
Data 
collection 
day 2
Complications of stroke 
treatments received
x
Data 
collection 
day 90
Discharge destination, 
assistance with activities 
of daily living and 
dependency (mRS)
x
Day 90 destination, 
assistance with activities 
of daily living and 
dependency (mRS)
x
Fig. 1 SPIRIT schedule of enrolment, interventions and assessments
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 Any previous medical history of transient
ischaemic attack (TIA) or stroke, which could
assist interpretation of brain imaging and
specialist evaluation of the risk versus benefit of
IV thrombolysis treatment
 The current level of dependency according to
whether the patient requires direct assistance with
feeding or walking, in order to judge the value of
administering IV thrombolysis treatment relative
to the effects of the new stroke
Within the pathway these information categories will
be prompted by the acronym PASTA, which represents
Plus dysphasia or visuospatial impairment; Anticoagu-
lant medications; Surgery or other bleeding recently;
TIA or stroke previously; Assistance needed daily.
2. Pre-notification. During emergency transfer the
paramedic will always be expected to attempt a pre-
alert to the destination hospital in accordance with
existing local arrangements. Although pre-
notification is already a component of standard care,
compliance is variable. Existing arrangements differ
within regional ambulance services and individual
hospitals, e.g. direct telephone contact from para-
medic, or via ambulance dispatch to ED or to HASU.
The individual hospital response can vary according
to the timing of the admission (e.g. the patient may
be received by a specialist stroke team during week-
day office hours and by ED clinicians at other times).
The PASTA pathway does not change local processes
but routinely prompts standard pre-notification.
3. Handover. On arrival at the hospital’s designated
location for stroke admissions, the paramedic will
provide a standardised handover of stroke-specific
information (FAST, onset time, alertness and
PASTA details) to the hospital team, indicating any
items which were unavailable at the scene. The
Fig. 2 PASTA pathway
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paramedic will ask the receiving hospital team
whether it is possible to go straight to the CT scan
if the radiographer is ready and will remind them
about ideal time targets for scan (< 15 min) and IV
thrombolysis treatment (< 30 min). A member of
the ambulance crew will assist the team with rapid
registration of the patient’s details on the hospital
patient administration system. Prior to CT scan, a
hospital clinician will always confirm that the
provisional diagnosis is likely to be stroke within
the previous 4 h. In addition, the paramedic will in-
form the team about the known location of any rel-
atives in order to facilitate information gathering,
communication and treatment decisions.
4. Scan. If the CT scan is immediately available, the
paramedic will assist with patient transfer to the
scan room accompanied by at least one member of
the hospital team. It will be a local decision whether
the patient is first transferred onto a hospital
trolley, but any delays should be minimised.
5. Assist. If the CT scan is not immediately available,
the hospital team will continue with urgent care of
the patient according to the local service protocol,
and the patient will be transferred onto a hospital
trolley. If ambulance service operational conditions
are suitable and the hospital team require
assistance, the paramedic can assist with the
following tasks: insertion of an intravenous cannula
if not already inserted; determining the patient’s
weight from assisting with transfer onto
measurement scales or contributing towards a team
estimation of weight; and repetition/clarification of
clinical information (e.g. repeating the handover to
a member of the stroke team). If the scan becomes
available within 15 min of handover, the paramedic
will assist with the patient transfer as above.
6. Checklist. At 15 min after handover the paramedic
will ask a member of the hospital team to confirm
progress with key tasks: the status of the emergency
brain scan request (if not yet performed) and stroke
specialist review; confirmation of relevant medical
history and medications; and ordering blood tests
for clotting indices if relevant.
7. Feedback.After completion of the checklist, the
paramedic will request feedback from a hospital
clinician about the provisional pre-hospital diagno-
sis of stroke, the estimation of onset time and any
other aspect of the assessment process.
8. Completion. After seeking the checklist and
feedback information, the paramedic will complete
and sign the study documentation. The paramedic
will depart as per usual operational procedure. This
will be within 15–30 min of hospital arrival and
therefore compliant with NHS Commissioning
Board guidance for ambulance to hospital handover
of emergency admissions [24].
The paramedic will record a reason if study documen-
tation is signed before completion of the PASTA path-
way. Anticipated reasons are:
 The paramedic is no longer contributing towards
the clinical care of the patient.
 A change in the clinical state of the patient making
the PASTA pathway no longer appropriate (further
details below).
 A stroke mimic condition is clearly identified during
the initial hospital assessment, and the hospital team
determine that it would no longer be appropriate to
continue with a care pathway for suspected stroke
(further details below).
 A specific request by the regional ambulance
control centre that the ambulance crew should
become available for another call due to the
pressure on resources.
Permitted local variations to the PASTA pathway
Due to pre-existing variations in standard care clinical
pathways and underlying healthcare service structures,
there will be permitted variations in the different stages
of the PASTA pathway as shown in Table 1.
Clinical deterioration During the pre-hospital phase of
the PASTA pathway, if the patient’s condition deterio-
rates, then the paramedic will re-evaluate whether it is
still appropriate to continue with the pathway according
to his/her professional judgement and standard clinical
protocols. The reason for any deviation will be recorded,
including the anticipated clinical scenarios of falling con-
scious level, seizure, hypotension and hypoglycaemia.
Stroke mimic conditions Early identification of stroke
patients is challenging, because other conditions (‘stroke
mimics’) can create similar symptoms through different
mechanisms, e.g. unwitnessed epileptic seizures and mi-
graine. In clinical practice approximately 26% of patients
who are suspected to have had a stroke in the
pre-hospital setting receive a stroke mimic diagnosis fol-
lowing admission to hospital, brain imaging and stroke
specialist review [25]. Thrombolysis treatment is in-
appropriate for these patients. If a stroke mimic condi-
tion becomes apparent during the initial hospital review,
the hospital team will discontinue the IV thrombolysis
assessment process as per standard clinical care.
Standard stroke care (comparison group)
Patients with suspected stroke symptoms attended by a
control group paramedic receive standard stroke care as
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per current local ambulance and hospital clinical proto-
cols, which are reinforced by national clinical guidelines
and audit. The study does not provide comparison group
paramedics with additional training or documentation to
support information collection, clinical communication
or processes after hospital arrival.
Study participants
Patients are identified and approached about enrolment in
the study after arrival at hospital (further details are pro-
vided in the subsequent section on ‘Participant identifica
tion, recruitment and consent’). Patients approached
about enrolment meet the following criteria:
 Travelled to hospital with a study paramedic
 Aged 18 years and over
 Hospital specialist diagnosis of stroke
 Within 4 h of stroke onset (onset time determined
by the hospital stroke team) when assessed by the
study paramedic.
Participant identification, recruitment and consent
Patients are identified and recruited and will consent to
take part in this study after arrival at hospital and when
the IV thrombolysis treatment assessment has been
completed. There is no study enrolment process in the
pre-hospital setting. The purpose of the study is to dem-
onstrate that the PASTA pathway can expedite the clin-
ical delivery of a treatment which is already known to be
effective in reducing future disability but must be ad-
ministered rapidly (IV thrombolysis). A formal research
consent process performed by study paramedics or the
admitting hospital team would delay hospital admission,
brain imaging and/or IV thrombolysis treatment. Due to
the time-dependent effect of IV thrombolysis, even a
short delay could reduce the impact of the PASTA path-
way. As the pathway does not involve a new treatment
or technology but is attempting to expedite an existing
hospital care process using a structured clinical assess-
ment performed by paramedics, the risk of harm to
intervention patients is low. Patients will still only re-
ceive IV thrombolysis treatment following review by a
stroke specialist. Although they do not provide study in-
formation to patients, as per usual clinical practice, para-
medics explain to patients about possible care processes
which may occur in hospital.
In order to identify study-eligible patients, hospital
research staff systematically review the ambulance and
hospital records of all admitted patients with a con-
firmed hospital specialist diagnosis of stroke. Patients
meeting the enrolment criteria are approached about
taking part in the study.
Ideally, patients are approached during their inpatient
stay such that a timely discussion about the study can be
held. However, as some patients are discharged very
early after admission and identification of eligibility may
only occur after discharge, postal invitations to take part
in the study are also used.
The participant eligibility assessment process is shown
in Fig. 3.
Identification of confirmed stroke patients is facilitated
by national clinical guidelines and audit, which mandate
that all stroke patients should be admitted to the HASU
within 4 h of hospital arrival, irrespective of the timing or
Table 1 Permitted local variations to the PASTA pathway
PASTA component Core content expected to be delivered Local variation permitted
Information Must use PASTA format Any clinical information collection system (paper/electronic)
Pre-notification Must be performed for all PASTA admissions Paramedic call to ED
Paramedic call to HASU
Dispatch call to ED
Dispatch call to HASU
Pre-notification may or may not include patient-identifiable information
Handover Must follow study format Occurs in most suitable area for rapid handover and registration
Receiving hospital team are ED and/or stroke service clinicians
May include other relevant information for individual patients
Scan Paramedic assists with transfer to scan if
< 15min since handover
Any appropriate hospital clinician accompanies patient
Any brain imaging modality which would assist treatment decisions
Transfer by ambulance or hospital trolley as long as no delay incurred
Assist Patient transferred off ambulance trolley onto
hospital trolley
Paramedic offers assistance for initial tasks
Ambulance crew prepares for departure
Team may not require assistance for each or all task(s)
Ambulance operational conditions may shorten paramedic stay
Checklist Paramedic enquires about progress from any
hospital team member at 15 min since handover
Checklist completion should reflect usual local service procedures (e.g.
telemedicine specialist review)
Feedback Paramedic seeks feedback about provisional
diagnosis and onset time
Any member of hospital team can provide feedback
Paramedic can seek feedback on any aspect of the assessment
The hospital team may not (yet) be able to provide feedback
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the local service configuration [4, 8]. It is still possible that
a small number of stroke patients attended by a study para-
medic will not be admitted to the local HASU because of:
– Transfer to a neuroscience centre for possible
surgical or neuro-interventional treatment
– Very quick recovery and discharge
– Bed availability in the local HASU
– Death before transfer from the ED to the HASU
In order to reduce the chance of these patients not be-
ing located in hospital, where possible, participating am-
bulance services send a regular site-specific report of all
suspected stroke patients admitted by study paramedics
to each participating site. Hospital research staff use this
report to check the hospital diagnosis assigned. Where
the diagnosis is confirmed stroke, other study eligibility
criteria are reviewed and patients are approached about
the study as appropriate.
Patients for whom a study paramedic suspects a stroke
within 4 h of symptom onset (and as such should receive
the PASTA pathway if seen by a trained intervention
group paramedic), but who receive at hospital an alterna-
tive diagnosis (‘stroke mimics’) and/or an onset time
which means the stroke commenced greater than 4 h ago
are not approached about study enrolment. Although not
contributing towards the study outcomes, the number and
nature of stroke mimic conditions and whether or not IV
thrombolysis was administered is recorded.
Consent
The consent process seeks permission for the use of rou-
tinely recorded healthcare data and for one study-specific
assessment at day 90 after stroke (see the ‘Study data col
lection’ section later in the paper). In order to ensure that
all eligible patients are provided with an opportunity to
participate, several consent options are in use.
Consent for patients who can be approached about study
participation during their inpatient stay
Consent for patients with mental capacity For eligible
patients with capacity to consent to research, hospital
research staff approach the patient to discuss the study
and provide a patient information sheet. After allowing
sufficient time for a decision about whether to take part
in the study and an opportunity to ask questions, con-
sent is obtained in writing.
When a patient has mental capacity but is unable to
sign the consent form (e.g. because of weakness of the
dominant hand following stroke), consent is confirmed
orally in the presence of a witness (an individual not
Fig. 3 Identification of patients to approach for study participation
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otherwise involved in the trial), and the witness signs
and dates the consent form on behalf of the participant.
Consent for patients with mild communication
difficulties For patients with mild communication diffi-
culties due to the effects of stroke upon the use and un-
derstanding of language (aphasia), a set of ‘easy access’
study documentation is used. After allowing sufficient
time for the information (including an ‘easy access’ pa-
tient information sheet) to be considered and an oppor-
tunity to ask questions, consent is obtained in writing
using the ‘easy access’ consent form.
Consent for patients who lack mental capacity It is
anticipated that approximately one third of study-eligible
patients will be unable to engage with an informed
consent process due to the effects of stroke upon com-
munication and cognition. As exclusion of this group
would drastically reduce the clinical relevance of the
study, if a patient has been identified as eligible but lacks
the capacity to consent, a personal or professional con-
sultee is approached.
Hospital research staff first attempt to identify an ap-
propriate personal consultee (usually the next of kin) in
order to discuss the study and provide a consultee infor-
mation sheet. If a personal consultee is identified, after
allowing sufficient time for him/her to consider the pa-
tient’s wishes and feelings and an opportunity to ask
questions, the consultee is asked to complete a consultee
declaration form if he/she believes the patient would
have no objection to taking part in the study.
If an appropriate personal consultee cannot be located,
an independent clinician (professional consultee) is
asked to confirm that the patient lacks capacity for con-
sent, and that study participation would not introduce a
risk of harm or be against the patient’s wishes from what
is known about the patient’s character and beliefs. The
independent clinician signs an independent clinician
declaration form concerning study participation.
As it is likely that the communication or cognitive diffi-
culties that impeded a patient’s ability to provide consent
will still be present at 90 days after stroke, where a
personal consultee provided permission to enter the study,
this person is contacted to complete the 90 day
study-specific outcome questions on behalf of the patient.
In cases where an independent clinician provided permis-
sion for study participation, only routinely available data
are collected at 90 days. The participant is not contacted.
Consent and early mortality The early mortality rate
following acute stroke is approximately 10%. These
patients are usually identified soon after admission and
treated palliatively. However, unexpected deaths also
occur. Exclusion of patients who die soon after admission
would reduce the study’s relevance for the typical clinical
stroke population.
When a patient has died, or if a formal palliative end
of life care process has been started at the point when
the patient is identified as eligible for the study, individ-
ual patient consent will not be possible, and it is likely to
be distressing for a personal consultee to be approached
regarding the research use of routinely collected health-
care data. The study-specific assessment at day 90 will
not be relevant. Under these circumstances the local
Principal Investigator (PI) signs an Early Mortality/Pal-
liative Care Declaration Form to confirm that the patient
has died or is in a formal palliative phase, and takes re-
sponsibility for the use of routinely collected healthcare
data for this research project.
Acute stroke has many effects upon neurological func-
tion and consciousness which can fluctuate for several
days or even weeks. Thus, there could be unusual in-
stances where a patient who has been entered into the
study using this Early Mortality/Palliative Care Declar-
ation Form subsequently may show enough signs of im-
provement that supportive care is re-instated, and may
still be alive at day 90. However, these are likely to be
challenging clinical situations where seeking an alterna-
tive method of consent will be difficult because of the
severe degree of remaining neurological impairment and
the time elapsed since admission. In these unusual sce-
narios, an alternative method of consent will not be pur-
sued, and the day 90 study-specific assessment will not
be conducted. Routinely available data collected as part
of standard clinical care will be retained as per the ori-
ginal PI declaration and used in the analysis.
Loss of capacity to consent to research during
participation in the study When participants have pro-
vided their own consent to take part in this research
project, it is possible that they may temporarily (e.g. be-
cause of intercurrent illness) or permanently (e.g. be-
cause of further stroke) lose the capacity to assist with
the 90 day study-specific assessment. On entering the
study, participants are asked to nominate a personal
consultee (a relative or close friend) who may be con-
tacted to answer the 90 day study-specific questions on
their behalf, should they be unable to undertake this as-
sessment personally.
Consent for patients who are only identified as study
eligible after discharge from hospital
Patients who are only identified as study eligible after hos-
pital discharge receive an invitation letter, patient informa-
tion sheet, consent form and pre-paid return envelope by
post. Patients willing to take part in the study are asked to
return a completed consent form. Invited patients who
have not returned a consent form within 4 weeks receive
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one phone call from the local hospital research team.
Thereafter, such patients will only be further contacted
about the study if a consent form is returned.
Figure 4 summarises the decision process for obtaining
study consent.
Study data collection
Data are collected day 1 pre-admission, day 1
post-admission, day 2 (if IV thrombolysis is adminis-
tered) and day 90 (+/− 7 days) post-stroke.
Day 1 pre-admission data
The following data are collected: suspected stroke diag-
nosis (FAST, paramedic judgement of stroke or query
stroke); symptom onset or last known to be well time
(paramedic judgement); pre-notification of receiving
hospital; times of 999 call, ambulance on scene, ambu-
lance left scene and hospital arrival; involvement of rapid
response paramedic (i.e. arrived by car or motorbike
ahead of the transporting ambulance): yes/no (interven-
tion group only); time of transfer of care (also called
handover) from the paramedic to the hospital team; time
of paramedic signature of the completed ambulance
clinical record; time paramedic is clear to respond to
another incident.
The above data are predominantly transcribed from
the routine ambulance clinical record onto a study-
specific Case Record Form (CRF) by hospital research
staff. However, some data items are not contained within
the routine ambulance clinical record but held within
computerised ambulance service dispatch systems.
These data are obtained directly from the ambulance
Fig. 4 Decision process for study consent
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services. For participants travelling to hospital with an
intervention paramedic trained to deliver the PASTA
pathway, some of the preceding data are also recorded
onto a study-specific paramedic CRF which additionally
records delivery of the PASTA pathway.
Day 1 post-admission data
The following data are collected: demographic informa-
tion (age, gender, pre-stroke mRS); date/time of hospital
admission; first blood pressure reading on admission;
first blood glucose reading on admission (capillary or
serum glucose); stroke severity on admission (NIHSS);
stroke onset or last known to be well time (stroke team
judgement); current use of anticoagulant medication;
previous medical history (stroke, TIA, heart failure, atrial
fibrillation, diabetes, hypertension); hospital admission
locations (ED, HASU, critical care, medical admissions
ward, other ward); first brain imaging time, modality and
result (CT/magnetic resonance imaging, infarction/pri-
mary intracerebral haemorrhage);thrombolysis treatment
decision (yes/no, reason why IV thrombolysis not admin-
istered); date/time of IV thrombolysis (if received); use of
other treatments (reversal of anticoagulation if haemor-
rhagic stroke, acute blood pressure lowering if haemor-
rhagic stroke or before IV thrombolysis, referral or
transfer to neurosurgery, referral or transfer for intra-
arterial treatment, use of intra-arterial treatments (yes/no,
time of puncture)); entry into another clinical trial on day
1 after admission (yes/no, which one); date and time of
admission to first HASU; date and time of assessment of
swallow safety at first hospital.
Day 2 IV thrombolysis outcome (if administered)
The following data are collected: stroke severity (NIHSS)
at 24–48 h after IV thrombolysis treatment (and/or
intra-arterial treatment if received): standard post IV
thrombolysis stroke severity measurement; complica-
tions (symptomatic intracranial haemorrhage/extracra-
nial bleed/angio-oedema/other complication) within 48
h of IV thrombolysis treatment (and/or intra-arterial
treatment if received): standard post IV thrombolysis
complications measurement.
The days 1 and 2 post-admission data are all routinely
collected clinical data. They are transcribed from routine
medical records onto a study-specific hospital CRF by
hospital research staff.
Day 90 (+/− 7 days) data
At day 90, data related to both hospital discharge from
the continuous inpatient episode and health at 90 days
after stroke are collected.
Data related to discharge due to completion of all
inpatient care The discharge data are as follows: died
during this inpatient episode for stroke (yes/no); cause
of death; date of death (if relevant); discharge date or
record that the patient is still an inpatient at day 90
(yes/no); if still an inpatient at day 90, has there been
stroke recurrence; discharge destination at completion
of this inpatient episode (own home, different private
address (e.g. relative) care home, other); if discharged to
a care home, was the patient previously resident/not
previously resident; rehabilitation arranged at discharge
(none, early supported discharge team, community re-
habilitation team, both); assistance with activities of daily
living required at discharge (yes/no, if yes: what support
received: informal carers/paid carers/both); if paid
carers, then how many visits per week provided at dis-
charge; dependency at discharge (mRS).
Data related to day 90 health The day 90 health data are
the following: died after stroke event discharge but prior to
90 days (yes/no); date of death (if relevant); cause of death (if
available); readmission(s) to hospital since discharge: reason
for admission(s), length of stay(s); readmission was due to
stroke recurrence (yes, no); current (90 day) residence (hos-
pital, home, different private address, care home, other);
current (90 day) dependency (simplified questionnaire mRS
[26]); community rehabilitation since discharge (therapy re-
ceived (yes/no), received at home/hospital/both, number of
weeks received, less than, equal to or greater than one ap-
pointment/week); current (90 day) assistance with activities
of daily living (yes/no, if yes: what support received: informal
carers/paid carers (how many visits per week)/both).
For all participants, confirmation that stroke remains
the diagnosis assigned for the event where consent was
obtained. If not, the new diagnosis assigned.
Day 90 data consist of both routinely collected clinical
data and study-specific data. Routinely collected clinical
data are transcribed from routine medical records onto a
study-specific CRF. Study-specific data are collected by
face-to-face interview, telephone interview or by postal
questionnaire. Telephone interview with the participant
or consultee is the main method and is undertaken by
hospital research staff.
In instances where a participant/personal consultee can-
not be contacted by telephone after one week of attempting
to locate him/her, a postal questionnaire is used. A postal
questionnaire is also used where telephone interview is not
be possible (e.g. participant does not have a telephone). A
single postal questionnaire with enclosed reply-paid
envelope is mailed. It is also possible to collect 90 day
study-specific data by face-to-face interview. This option is
used at the discretion of research staff but predominantly
when participants are currently hospital inpatients.
Where it has not been possible to obtain the 90 day
study-specific data by 6 months after stroke, research
staff use the routine hospital data administration systems
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to confirm whether the participant was alive or dead at
90 days. This is necessary because deaths in the commu-
nity can take some time to appear in the routine hospital
records. The mRS is scored 6 for death [27].
All study data are entered locally into a secure online
database.
Blinding
No specific blinding measures are in place. Paramedics
will know the study group allocation due to the nature
of the intervention. Participants will be informed about
group allocation if they ask for this information. Re-
search staff who conduct the 90 day research assessment
may be unaware of treatment group allocation, but this
will vary according to their involvement with partici-
pants on admission to hospital.
Staff training and awareness
For paramedics based within stations randomised to de-
liver the PASTA pathway, study-specific training is pro-
vided via a securely hosted online video. This includes
explanation of the study objectives, demonstration of the
PASTA pathway processes, completion of trial documen-
tation and responses to adverse events. After watching
the video, paramedics complete an online multiple
choice questionnaire knowledge assessment (MCQ).
Paramedics who do not provide correct responses to all
questions are invited to watch the online video again
and repeat the MCQ. Paramedics who correctly answer
all questions are identified as trained and issued study
documentation. If paramedics based with stations allo-
cated to delivering the intervention do not wish to assist
with the study, they can opt out of training.
Paramedics based with stations randomised to con-
tinuing standard stroke care are informed that there is
an ongoing study of pre-hospital assessment for stroke
patients, but they are not given any further information
about the study, and they are asked not to change their
practice. Paramedics allocated to continuing standard
stroke care can also opt out of the study if they wish.
To determine whether the characteristics of para-
medics participating in each study group differ, the fol-
lowing will be obtained about individual randomised
paramedics during the course of the study: age, gender,
highest qualification, years qualified as a paramedic,
years in service at employing ambulance service, NHS
job band, job title. These characteristics will be obtained
by means of an electronic survey.
Research staff based in hospitals receive study-specific
training including identification, recruitment and con-
sent of participants, data collection and the 90 day re-
search assessment, as well as other study processes such
as use of the online database.
Clinical staff at hospitals taking part in the study are
made aware of the trial at service meetings and by email
but do not receive additional protocol-related research
training or documentation. Hospital services are not ex-
pected to change their standard local care process for pa-
tients undergoing IV thrombolysis treatment assessment
as part of the study. They will continue to provide clinical
care for all study patients consistent with the information
and prompts provided by all paramedics within the con-
text of the local service setting. If services change their
configuration and standard care process during the study
as a quality improvement initiative, this would apply to all
stroke admissions and would not prevent the delivery of
the paramedic-led PASTA intervention.
Study withdrawal
No specific withdrawal criteria have been pre-set. Partic-
ipants may withdraw from the study at any time for any
reason. Data collected prior to withdrawal will be used in
the study analysis unless the patient or the patient repre-
sentative requests that this should not be the case. Should
a decision to withdraw from the study be made, a reason
for withdrawal will be sought, but participants can chose
to withdraw without providing an explanation.
Occasionally, further clinical tests and information ob-
tained result in a diagnosis of stroke being revised to an
alternative diagnosis at a later date. Such patients will
not be withdrawn from the study, as the initial care pro-
cesses received were for a diagnosis of stroke.
Safety evaluation
The PASTA intervention is designed to expedite standard
stroke care and in particular IV thrombolysis treatment.
Thrombolysis treatment is widely used in clinical practice,
and its adverse events are well described. Administration
cannot be repeated within 4.5 h of stroke onset, and all
pharmacological action has been lost within 24 h. The
PASTA intervention does not change the clinical criteria
for IV thrombolysis administration; therefore, it is not
possible for any adverse events after the emergency phase
to be attributed to the study intervention.
However, to ensure that any potential adverse effects
are recorded, this study is monitoring for serious ad-
verse events (SAEs) for 7 days after study entry (para-
medic assessment) and recording all deaths for the
duration of a participant’s involvement in the study
(until 90 days after stroke).
A study SAE form is completed for all events fulfilling
the standard definition of an SAE with the expection of
the following, which have been excluded from SAE
reporting:
– Pre-planned hospitalisations and scheduled
treatment for pre-existing conditions
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– Events pre-defined as expected adverse events and
monitored in the main dataset (death due to initial
stroke, IV thrombolysis-related cerebral haemorrhage
and stroke recurrence leading to new hospitalisation).
Statistical analysis
Analysis is by ‘treatment allocated’; that is, primary and
secondary effectiveness and safety outcome analyses will
use the study group allocation of the station base for the
attending paramedic.
The primary end point measure is the proportion of
participants who received IV thrombolysis. The primary
analysis will use logistic regression to compare the pro-
portion of participants who received IV thrombolysis in
the two arms of the study. Models will include clinically
and statistically important covariates and factors, includ-
ing (but not limited to) participant age and gender and
admission time and date (used to define a covariate to
reflect background trends).
Secondary outcomes, including stroke severity 24 h
after IV thrombolysis (measured by an NIHSS score), in-
patient mortality and dependency (mRS), will be ana-
lysed by appropriate ordinal and binary regression
models, with appropriate adjustment for potential covar-
iates and factors.
To address the second objective (that is, the impact of
the intervention on the time intervals related to the emer-
gency call), appropriate statistical models will be used. For
time intervals between events which always happen (for
instance, emergency call to hospital admission), linear
models will be employed (after appropriate transform-
ation), again adjusting for statistically significant covariates
and factors. If the distributions of residuals are markedly
non-normal, further transformation or bootstrapping will
be considered. Residual diagnostics will also be used to
identify outliers; identified outliers will be excluded and
the analysis recalculated. For events which may or may
not happen (for instance, emergency call to IV thromboly-
sis), outcomes will be analysed via binary regression
models and survival analysis, comparing intervention and
control arms using the framework of accelerated life test-
ing; both approaches will again accommodate statistically
significant covariates and factors.
Other clinical objectives will be addressed by appropri-
ate descriptive statistical measures.
Sensitivity and subgroup analyses
Various sensitivity and subgroup analyses will be under-
taken to supplement evidence from the primary analysis
to help fully characterise the treatment effect. These will
include (1) analysis by ‘treatment received’; (2) analysis
of the study subgroup with a diagnosis of stroke
unchanged at 90 days; (3) others which are considered
important for understanding the study outcomes.
Subgroup analyses will generally, but not exclusively, be
undertaken for specific categories in factors with a sig-
nificant relationship with the primary outcome measure.
These analyses are either confirmatory or exploratory
and, as the study is not statistically powered for multiple
analyses, their results will be interpreted in this context.
Missing data
In general, we shall endeavour to adopt a consistent ap-
proach to missing data relating to both clinical and cost
effectiveness, except where individual outcome measures
require variation in that approach. For each variable, we
shall summarise the frequency of missing data, which af-
fects effective sample size and hence statistical power. If
there is no reason to suspect that data are not missing
completely at random (MCAR), we shall consider the
use of appropriate imputation methods to ameliorate the
problem of missing data; otherwise, the Trial Statistician
and Chief Investigator will further discuss patterns in
missing data.
Reporting
Outcome descriptions, summaries and comparisons will
be expressed in accordance with appropriate Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines [28], including estimates with 95% confidence
intervals to summarise two-tailed tests at the 5% signifi-
cance level.
Sample size
The sample size for this study postulates a change from
0.43 to 0.53 in the proportion of patients receiving IV
thrombolysis (equivalent to a standardised statistical effect
of 0.2). Using 90% power, 5% significance, an average clus-
ter (patients per paramedic) of 5, an intra-cluster correl-
ation coefficient of 0.02, an imbalance of 2 control
patients per intervention patient and attrition of 1%, 1297
participants are required (865 control cases versus 432
intervention cases). An imbalance of control and interven-
tion patients is included in this calculation because it was
apparent early in the study that more control patients
were being enrolled than intervention patients. This is be-
cause paramedics randomised to the intervention group
are not considered part of the study unless they complete
the study-specific training, and training rates are not as
high as had initially been anticipated. This is resulting in
more patients being conveyed to hospital by control than
intervention paramedics. The emerging imbalance was
considered during a sample size revision in 2017 (see the
‘Trial status’ section for further details about revisions to
the study in 2017).
The final recruitment target is being kept under re-
view, as should the attrition rate or imbalance ratio
change during the ongoing course of the study, it may
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be necessary to adjust the target accordingly to achieve
the required number of control and intervention analys-
able outcomes needed to maintain statistical power.
Economic analysis
The primary economic analysis will be a within-trial
evaluation to estimate the cost effectiveness of the en-
hanced role versus standard stroke care for increasing the
proportion of patients receiving IV thrombolysis, and will
report a cost per additional patient thrombolysed. In
addition a cost utility analysis will be conducted to esti-
mate cost per quality-adjusted life years (QALYs) gained.
Estimation of QALYs
Pre-stroke and 90 day mRS scores will be used to esti-
mate QALYs. EuroQoL five dimension (EQ-5D) scores
will be generated using mapping algorithms which have
been developed by Whynes et al. [29] and Rivero-Arias et
al. [30]. Mortality and utility values will be converted into
QALYs using the area under the curve method, control-
ling for baseline health utility derived from mRS [31].
Estimating the resources used and costs for providing an
enhanced paramedic role
The costs of paramedic time will be based on the
equivalent hourly wage for the appropriate grades. The
time taken to complete the training will be recorded by
the computer-based training software. Training material
productions costs will be excluded. The times from the
‘on scene’ to ‘handover’ and ‘clear to respond to another
incident’ will be recorded and used to estimate add-
itional ambulance service resource utilisation resulting
from the enhanced paramedic role. The resource costs
will be obtained from Ambulance Trusts and published
sources including the Personal Social Services Research
Unit (PSSRU) [32].
Estimating the consequences for resources resulting from
an enhanced paramedic role
Data on the use of NHS inpatient resources will be col-
lected for patients in both arms of the trial. These data
will comprise brain imaging modality, provision of IV
thrombolysis and length of stay in hospital. In addition,
data about community rehabilitation therapy, social ser-
vice involvement and non-elective episodes of secondary
care post-discharge will also be collected at the days 1/2
and day 90 data collection points. Unit costs will be de-
rived from routine sources for NHS and social care. The
costs of providing the PASTA pathway for stroke mimic
patients will be included but also presented separately.
This will represent an economic worst-case scenario, be-
cause costs will be added, but it will be assumed that
there is no benefit (or harm) to these individuals. If the
intervention still appears cost effective in this scenario,
then the trial conclusions would be strengthened.
Estimating cost effectiveness
Bootstrapping analysis of healthcare costs and outcomes
will be used to estimate the mean differences and 95%
confidence intervals between the enhanced role and
standard care groups. The results will be presented as the
point estimate of a mean incremental cost-effectiveness
ratio (ICER) for the enhanced paramedic role versus
standard care. The ICER will be calculated as a
between-group difference in costs divided by the differ-
ence in effects (i.e. the proportions receiving IV thromb-
olysis and QALYs).
Missing resource use data
If there are data missing on post acute resource usage,
essential items will be imputed from data present in the
study for similar patients as defined by age, stroke sever-
ity and 90 day outcome [33]. Sensitivity analysis will
quantify the degree of bias introduced by imputation.
Sensitivity analyses
Both stochastic and deterministic sensitivity analyses will
be performed by non-parametric bootstrapping, includ-
ing exploration of using different unit costs. Stochastic
outputs will be presented as a cost-effectiveness plane
and cost-effectiveness acceptability curves [34].
Long-term economic evaluation
In common with other economic evaluations, a further
modelling analysis will be undertaken to extrapolate the
results of the trial beyond the 90 days, and consider pos-
sible longer-term costs and effects. The model will be a
microsimulation state transition model made up of three
states (independent, dependent and death) to which
costs and QALYs will be attached [35]. To estimate the
longer-term effects of increased independence that may
result from an enhanced paramedic role, the economic
model will describe changes in dependency status over
time. Outcomes after subsequent recurrent strokes will
be estimated using a published decision analytic model
(DAM) which predicts the outcome with and without IV
thrombolysis [36]. The validity of the model will be con-
firmed against those 90 day outcomes available in the
trial dataset.
Quantifying uncertainty in estimates of cost effectiveness
Both deterministic and probabilistic sensitivity analyses
based on a Monte Carlo approach will be used to estimate
the uncertainty in the economic model with results pre-
sented in the same format as the within-trial analysis. If
after initial analysis it is found that the cost effectiveness
of the intervention is sensitive to one or more inputs, an
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expected value of perfect parameter information (EVPPI)
will be undertaken focussing on those inputs [37].
Qualitative evaluation
A qualitative process evaluation is being undertaken to
report upon patient experience and professional views
(paramedics and hospital staff ) regarding the acceptabil-
ity and feasibility of the PASTA pathway in the clinical
setting. Patients and professionals are invited to partici-
pate in semi-structured interviews:
1. Medically stable patients who were attended by an
intervention paramedic and provided their own
consent to participate in the trial.
Following written informed consent, individual
face-to-face interviews with a subgroup of patients
enrolled in the trial are conducted by a qualitative
researcher. Whenever possible, such interviews are
arranged within 7 days of admission to facilitate re-
call of experiences and details.
2. Paramedics.
Interviews are being conducted with intervention
group paramedics, both those who have and have not
completed the training. Interviewing non-trained
intervention paramedics was introduced as a revision
to the study in 2017 when it became apparent that
training rates were not as high as anticipated. This
made it important to understand barriers and facilita-
tors to the deployment of the intervention should it
be found to be of value for patient care.
For intervention group paramedics who have
completed training, purposive sampling aims to
ensure representation of a range of times since use
of the PASTA pathway (less or more than 30 days,
no activations since training); paramedic seniorities
(years of practice, employment title); base station
setting (urban, rural); and experience of different
patient admission routes (via ED, direct to HASU).
For intervention paramedics who have not
completed training, selection for interview aims to
represent only each ambulance service and base
station setting (urban, rural), as further information
about non-trained paramedics is not captured dur-
ing the study processes.
According to availability, focus groups or individual
interviews (in person or by telephone) are being
conducted. Individual paramedics may be invited
for interview on more than one occasion. For
intervention group paramedics who have completed
training, interviews focus on understanding views
about delivery of the study intervention and the
training process. For intervention group paramedics
who have not completed training, interviews focus
(as appropriate) on why training has not been
undertaken and views on why they may or may not
undertake training if the intervention was part of
standard clinical care. In advance of the interview,
paramedics receive an information sheet and
consent form and are asked to return the consent
form by post, email or in person. Due to the
mobile nature of the paramedic workforce, it can
be prohibitive to ask for return of completed
forms prior to a telephone interview. If a
telephone interview is planned and it is not
practical to return the consent form by post or
email in advance, verbal consent is taken and
recorded before the interview commences. For
face-to-face interviews or focus groups, a written
consent form is completed.
3. Hospital professionals.
Focus groups with hospital professionals working in
the ED and stroke service who have witnessed the
PASTA pathway are conducted. Hospital
professionals are selected according to their clinical
role (doctor, nurse, radiographer); local patient
admission route (via ED or direct to HASU); and
the local IV thrombolysis assessment approach (in
person, telemedicine). According to availability,
focus groups or individual interviews (in person or
by telephone) are conducted. Individual
professionals may be invited for interview on more
than one occasion. In advance of the interview,
hospital professionals receive a consent form and
are asked to return it to the researcher conducting
the interview by post, email or in person.
Data collection
Separate patient and professional interview topic guides
are used to facilitate discussion. Data collection and ana-
lysis is occurring concurrently to allow for issues or
themes identified in earlier interviews to be explored in
more depth in subsequent interviews.
Data preparation and analysis
All interviews are digitally recorded and transcribed verba-
tim. In line with data protection legislation and research
governance frameworks, all information pertaining to
individuals/places is anonymised. The qualitative analysis
will adopt a constructivist grounded theory approach [38].
Open, then focussed coding, will be undertaken, and emer-
gent codes from the analysis of this stage will be presented
to the wider research team. A suitable software package (e.g.
NVivo) will be used to facilitate data analysis management.
Confidentiality
Personal data are regarded as strictly confidential.
Original paper CRFs containing study data are stored in
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the investigator site file at each research site. All study
files are securely stored, and access is restricted to staff
involved in the study. NHS research support staff at sites
enter data from paper forms into a secure web-based
electronic database. Data are entered using pseudo-
anonymised participant identification codes and, except
for the qualitative interview study where specific consent
has been obtained for contact details to be given to the
qualitative researcher, no identifiable information is
transferred out of the local site. Access to the database is
password protected and limited to staff at research sites
or staff involved in managing the study overall.
The study complies with the Data Protection Act
1998, and Caldicott Guardian approval for use of data is
sought in line with local requirements.
Trial monitoring, quality control and quality assurance
The Chief Investigator has overall responsibility for the
study conduct. The PIs are responsible for the
day-to-day study conduct at their individual sites.
The trial is managed by a co-ordinating centre staff
based at Newcastle University who provide day-to-day
support for the sites and provide training through inves-
tigator meetings, site initiation visits and routine moni-
toring visits. A Trial Management Group (TMG) has
been convened and meets regularly during the study.
Quality control is maintained through adherence to
Newcastle Biomedicine Clinical Research Platform
standard operating procedures (SOPs), the study proto-
col and research governance regulations. General moni-
toring of study conduct and data collected is performed
by a combination of central review and site monitoring
visits. The main areas of focus include consent, SAEs
and essential documents in study files. All monitoring
findings are reported and followed up with the appropri-
ate persons in a timely manner.
The study may be subject to inspection and audit by
Newcastle upon Tyne Hospitals NHS Foundation Trust
under their remit as sponsor.
A Trial Steering Committee (TSC) has been convened
to provide oversight of the trial. The TSC have agreed
on a charter of operation and meet at least annually.
An independent Data Monitoring and Ethics Commit-
tee (DMEC) is established. Only the DMEC has access
to unblinded outcome data before the trial ends. The
DMEC have agreed on a charter of operation and meet
at least annually.
Dissemination of results
The study will be presented at national and international
conferences and reported in peer-reviewed journals. Re-
ports will be written for the study funder, sponsor and
regulatory bodies. Anonymised data will be provided to
research databases as requested (e.g. the Cochrane Col-
laboration) to enable future meta-analyses.
Discussion
Improved timely access to acute stroke treatments is re-
quired. To date, most intervention has focussed on re-
sponses after patient admission to hospital, such as
activation of a highly co-ordinated specialist team re-
sponse. As the identification of and care for the majority
of stroke patients is commenced pre-hospital by para-
medics, simple enhancements to their routine processes
may contribute towards improved access to specialist
care, notably IV thrombolysis. This study will determine
whether a Paramedic Acute Stroke Treatment Assess-
ment (PASTA) care pathway improves access to IV
thrombolysis and other aspects of stroke care.
Trial status
The PASTA trial commenced recruitment in December
2015. The North East Ambulance Service, North West
Ambulance Service and Welsh Ambulance Service are
participating along with 12 NHS Hospital Trusts in Eng-
land and 2 Health Boards in Wales. At the time of submis-
sion of this manuscript, 1038 patients were enrolled in the
trial. Recruitment is scheduled to end in summer 2018,
and results will be submitted for publication in 2019.
Protocol version 2 dated 31 October 2017 was used to
prepare this manuscript. Amendments to the study
which resulted in updating the protocol from version 1
to version 2 included the following:
 Changing the primary outcome (from a health
outcome measured at day 90 by the mRS score to
the proportion of patients receiving IV
thrombolysis) and therefore modification of the
sample size accordingly
 Addition of a group imbalance to the new sample
size because of the incomplete uptake of study
training by paramedics randomised to the
intervention group
 Addition of a postal consent option
 Broadening the clinician interviews in the qualitative
evaluation to include paramedics who had not
completed the intervention training
 Alteration of the health economic analysis to align
with the new primary outcome and inclusion of
modelling of the health impact of the intervention
The change to the primary outcome decreased the re-
quired sample size. Decreasing the sample size was ne-
cessary, because the study recruitment rate was too low
to achieve the original sample size in a reasonable time-
frame.The new primary outcome is directly related to
the previous primary outcome, as clinical trials have
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shown that receipt of IV thrombolysis carries a known
probability of changing health outcomes. The new pri-
mary outcome is therefore reporting the direct impact of
the intervention upon a patient care process which has
predictable results for health outcomes.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
1290 Q12 in a clinical trial protocol and related documents. (DOC 122 kb)
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